Retrospective Kuwait registry study of 2629 RA pts- 2326 (88.5%) w/ early (EORA) vs 303 (11.5%) late(LORA). LORA had more age related comorb. Dz (2 vs. 0.9), similar DAS28/CDA, but signif higher ESR (41 vs 33). T2T applies regardless of age!! https://t.co/MK8SfjcxCA https://t.co/ZxHwt8qxvT

FDA has approved rembrutinib (Rhapsido - BTK inhibitor from Novartis)as 1st Rx for adults with dermographism not controlled by H1 antihistamines (expanding its use beyond chronic spontaneous urticaria) https://t.co/wytr6veoZJ https://t.co/czFmLHFuL3

GLP-1 Receptor Agonists in Rheumatology Created for RheumNow by @MithuRheum https://t.co/VvNBbEYfE5 https://t.co/wFhQ4WAtA2

Agenx announced it will discontinue its phase 3 UNITY study -efgartigimod SC in adults with mod-to-severe Sjögren's dz, based on not meeting its primary endpoint (clinESSDAIwk 48) & rec from DSMB. ""Sjögren's Disease is one of the most heterogeneous and complicated diseases in https://t.co/fmuzxvaCGx

“It’s also critically important to take the GI tract into consideration” – Dr. Joshua Steinberg, Gastroenterologist Watch to learn how GI symptoms can signal a need for coordinated care in PsA. Sponsored by AbbVie Medical Affairs + Health Impact. https://t.co/3Y68R2Pgb3 https://t.co/hX0Miq1d8P

Retrospective cohort study of 387 ANCA-assoc. vasculitis pts Rx w/ GC +/- avacopan (AVA 52 vs 335 not Rx AVA). AVA use assoc w/ signif less severe infx (adj HR 0.22), & less pred use - but no diff in relapse risk was observed. https://t.co/GTtAf7KiqB https://t.co/ElipLLBm63

POETYK PsA-1 - Efficacy and Safety of Deucravacitinib in Psoriatic Arthritis van der Heijde et al have published the results of the phase 3 POETYK PsA-1 trial demonstrating that deucravacitinib was superior to placebo in clinical responses, patient-reported outcomes, and https://t.co/ovASDqLeWK

Giant Cell Arteritis market size was valued approximately $960 million USD in 2023 - read for interesting drug developments in GCA arena https://t.co/pEZ95je7r0 https://t.co/Dz8D5ieDQp

EBR Journal Club: Brepocitinib in Dermatomyositis (VALOR) The EBR Journal Club Companion applies my adapted version of the JAMA approach to critical appraisal. Each review covers four domains: Does this apply to my patients? What is the risk of bias? How great are the benefits https://t.co/KUB7fpmdbf

Exercise Can Improve Pain A pooled meta-analyses (n=197,392) shows that exercise reduced pain versus control immediately after the intervention (SMD −0.59; 95% CI −0.65 to −0.53; P<0.001). The benefit held across musculoskeletal, inflammatory, neurologic and cancer pain, and https://t.co/rbZlyfrCOW

Study of 64 Stills related #MAS pts (55 sJIA; 9 AOSD). All Rx GCs; 75% anakinra, 52% ciclosporin. Complete remission in 7, partial Rem in 64%; GCs tapered in 78% in median 40d. MAS recurred in 31%; 11% died; 1-year survival probability 93.75% https://t.co/HxhhpRsSMO https://t.co/IQHLRlULcP

Retrospective real world avacopan (AVCP) safety data from UK vasculitis center looked at AAV pts (RTX or CTX) rx w/ AVCP (n 133) or not AVCP (n 458). @1 yr AVCP had nonsignif incr in ALT >2xULN (15.8% v 11.4%) or >3xULN (11.3% v 6.3%; P 0.064) No diff in Alk phos, Bili, Hy's law https://t.co/ZZhpxdKhQl

43 biopsy-proven Giant cell arteritis in Black Caribbeans - GCA incidence rate 1.76/100K pY (1/2 rate of whites) w/ 4 fold incr betw 1993 & 2014. Mean Age 76; F:M ratio 4.4. Initial Sxs HA (65%), jaw claud (33%), scalp tender (37%), anterior ischemic optic neuropathy (26%) & PMR https://t.co/lHAeNdOqbj

Triple Hormone Receptor Agonist for Treatment of Obesity and Knee Osteoarthritis The NEJM reports that retatrutide, an investigational incretin agent, was shown to yield up to 25% weight reduction, with subanalyses also showing reduced pain with knee osteoarthritis, and less https://t.co/18DM2UL6vB

UK longitudinal study 46 adult PsA pts w/ BMI ≥25 showed use of digital wt. & Dz app (vs no app) improved weight loss (− 1.55 vs − 0.18 kg), dz activity by CPDAI (p < 0.001), esp w/ arthritis (p 0.017) & enthesitis (p  0.034) domains. Weight loss correlated w/ dz activity https://t.co/Y9zVyPmsNl